Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges

Table 3 Specialist recommendations and follow-up outcomes

Specialist recommendation	n	Regimen prescribed matched regimen recommended by specialist	Regimen prescribed did not match regimen recommended by specialist	Continued first-line regimen despite recommendation for switch	Data missing
Standard second-line ART*	324	247 (76.2)	17 (5.2)	39 (12.0)	21 (6.5)
Other standard second-line ART†	41	22 (53.7)	9 (22.0)	8 (19.5)	2 (4.9)
Non-standard second line ART‡	21	7 (33.3)	10 (47.6)	1 (4.8)	3 (14.3)
Non-standard salvage regimen§	3	0	2 (66.7)	1 (33.3)	0
Continue first-line ART	49	39 (79.6)	10 (20.4)	NA	0
Total	438 (100)	315 (71.9)	48 (11.0)	49 (11.2)	26 (5.9)

*Second-line regimen recommended by national guidelines in the absence of genotypic resistance testing (based on treatment history).
^†Second-line regimen included in national guidelines but not the regimen that would have been prescribed based on treatment history.
^‡Alternative second-line regimen incorporating only drugs in national guidelines (e.g. 3 nucleoside reverse-transcriptase inhibitors and protease inhibitor).
^§Alternative regimen incorporating novel antiretroviral agents (e.g. raltegravir, etravirine).

ISSN: 1472-6963